Leukemia drug appears to stop early stage MS - Reuters
LONDON (Reuters) - A drug developed to fight leukemia appears to stop multiple sclerosis in its early stages and restore lost function to patients, British researchers said on Wednesday. The three-year study of Bayer AG and Genzyme Corp's alemtuzumab

Silencing a protein might prevent leukemia - United Press International
People who read this also read Gene mutation ups leukemia drug's effect Childhood leukemia drug resistance studied Genetic mutations linked to leukemia Drug might become new leukemia treatment Leukemia survivors have lifelong issues Lymphocytic

People making news - Detroit Free Press
The Michigan Chapter of the Leukemia & Lymphoma Society has named Miriam Imerman as its new major gifts officer. Imerman, who was the director of planned giving for the Henry Ford Health System, is in charge of developing, implementing and growing

Jeremy Beadle Dies - Entertainment.uk.msn.com
The showbiz world mourns TV presenter Jeremy Beadle who has died after battling pneumonia. He was one of ITV 's biggest stars in the 1980s. TV star Jeremy Beadle has died at the age of 59. He was in intensive care battling pneumonia when he lost

Biovest and IDIS Announce Agreement to Launch Named-Patient Program - MSN MoneyCentral
Biovest International, Inc. BVTI , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. ABPI , today announced that it has executed a distribution agreement with IDIS Limited to exclusively supply BiovaxID (personalized, anti-idiotype

Neil Diamond tribute night is fundraiser for child with leukemia - Daily Observer
He looks nothing like Neil Diamond, more like Patrick Swayze, say fans. It is a given that after every performance there will be at least a couple of women who ask Joey Purpura if he knows who he looks like. "As soon as I hear, 'Do you know who you

Biovest plans cancer drug sales in Europe - Tampa Bay Business Journal
Biovest International Inc. said it has a distribution agreement to supply its personalized cancer vaccine in parts of Europe. The vaccine, BiovaxID, will be sold under a named-patient program in France, Germany, Italy, Greece, Spain and the United